Toll Free: 1-888-928-9744

Dilated Cardiomyopathy - Pipeline Review, H1 2016

Published: Feb, 2016 | Pages: 59 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Dilated Cardiomyopathy - Pipeline Review, H1 2016

Summary
Global Markets Direct's, 'Dilated Cardiomyopathy - Pipeline Review, H1 2016', provides an overview of the Dilated Cardiomyopathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dilated Cardiomyopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dilated Cardiomyopathy and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Dilated Cardiomyopathy - The report reviews pipeline therapeutics for Dilated Cardiomyopathy by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Dilated Cardiomyopathy therapeutics and enlists all their major and minor projects - The report assesses Dilated Cardiomyopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Dilated Cardiomyopathy Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Dilated Cardiomyopathy - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Dilated Cardiomyopathy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Dilated Cardiomyopathy Overview 6 Therapeutics Development 7 Pipeline Products for Dilated Cardiomyopathy - Overview 7 Dilated Cardiomyopathy - Therapeutics under Development by Companies 8 Dilated Cardiomyopathy - Pipeline Products Glance 9 Clinical Stage Products 9 Early Stage Products 10 Unknown Stage Products 11 Dilated Cardiomyopathy - Products under Development by Companies 12 Dilated Cardiomyopathy - Companies Involved in Therapeutics Development 13 Array BioPharma Inc. 13 Capricor Therapeutics, Inc. 14 Hemostemix Ltd 15 Kasiak Research Private Limited 16 Sanofi 17 Vericel Corporation 18 Dilated Cardiomyopathy - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 ACP-01 - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 ARRY-797 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 CAP-1002 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 CIP-137401 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 DCM-1 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Drugs for Dilated Cardiomyopathy - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 ixmyelocel-T - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Refacell-DCM - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Dilated Cardiomyopathy - Recent Pipeline Updates 41 Dilated Cardiomyopathy - Dormant Projects 51 Dilated Cardiomyopathy - Product Development Milestones 52 Featured News & Press Releases 52 Jan 29, 2015: Vericel Completes Patient Enrollment in Phase 2b ixCELL-DCM Clinical Study of Ixmyelocel-T 52 Dec 19, 2013: Aastrom Biosciences Granted Composition-of-Matter Patent for Ixmyelocel-T in Australia 52 Dec 17, 2013: Capricor Therapeutics Cleared to Begin Phase II Portion of ALLSTAR Clinical Trial with CAP-1002 in Patients Following Heart Attack 52 Apr 19, 2013: Aastrom Biosciences Announces First Patients Treated In IxCELL-DCM Clinical Study Of Ixmyelocel-T 53 Jun 06, 2012: Aastrom Presents Preclinical Data Of Ixmyelocel-T At 18th Annual International Society For Cellular Therapy Meeting 53 May 10, 2012: Treatment With Ixmyelocel-T Shows Improvement In Outcome Of Heart Failure Patients 54 May 07, 2012: Aastrom To Present Phase IIa Trial Results Of Ixmyelocel-T In Dilated Cardiomyopathy Patients At SCAI Scientific Sessions 55 Oct 03, 2011: Aastrom Receives European Composition-Of-Matter Patent For Ixmyelocel-T 55 Sep 19, 2011: Aastrom Announces Positive 12-Month Safety And Efficacy Data From IMPACT-DCM Phase II Clinical Trial For Ixmyelocel-T In Treatment Of Dilated Cardiomyopathy 56 Sep 14, 2011: Aastrom To Present 12-Month Data From IMPACT-DCM Phase II Clinical Trial For Ixmyelocel-T In Treatment Of Dilated Cardiomyopathy 57 Appendix 58 Methodology 58 Coverage 58 Secondary Research 58 Primary Research 58 Expert Panel Validation 58 Contact Us 58 Disclaimer 59
List of Tables
Number of Products under Development for Dilated Cardiomyopathy, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Clinical Stage Development, H1 2016 9 Comparative Analysis by Early Stage Development, H1 2016 10 Comparative Analysis by Unknown Stage Development, H1 2016 11 Products under Development by Companies, H1 2016 12 Dilated Cardiomyopathy - Pipeline by Array BioPharma Inc., H1 2016 13 Dilated Cardiomyopathy - Pipeline by Capricor Therapeutics, Inc., H1 2016 14 Dilated Cardiomyopathy - Pipeline by Hemostemix Ltd, H1 2016 15 Dilated Cardiomyopathy - Pipeline by Kasiak Research Private Limited, H1 2016 16 Dilated Cardiomyopathy - Pipeline by Sanofi, H1 2016 17 Dilated Cardiomyopathy - Pipeline by Vericel Corporation, H1 2016 18 Assessment by Monotherapy Products, H1 2016 19 Number of Products by Stage and Target, H1 2016 21 Number of Products by Stage and Mechanism of Action, H1 2016 23 Number of Products by Stage and Route of Administration, H1 2016 25 Number of Products by Stage and Molecule Type, H1 2016 27 Dilated Cardiomyopathy Therapeutics - Recent Pipeline Updates, H1 2016 41 Dilated Cardiomyopathy - Dormant Projects, H1 2016 51



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify